SPARC and ovarian cancer: SPARC helps normalize the ovarian cancer malignant ascites microenvironment by downregulating the VEGF–integrin–MMP axis, reducing the levels and activation of bioactive lipids, and ameliorating downstream inflammatory (Said et al., 2007b).